Joint PSI/EFSPI Vaccine SIG Webinar: Statistical and Mechanistic Models for Correlates of Protection
This webinar will explore two different approaches to Correlates of Protection in vaccine development.
The London Mathematical Society, De Morgan House, 57-58 Russell Square, London, WC1B 4HS or via web-conference
PLEASE CLICK HERE TO VIEW THE RECORDED WEBINAR
The debate will take the form of short opening presentations providing background information on the current state of PSI finances and a summary of the PSI/RSS merger proposal. Following initial statements from the debaters in favour of and against the merger, questions and statements will be taken from the floor in person or from those attending online. Statements should be limited to 2 mins.
To help the meeting run smoothly, please submit a request to make a statement in advance to the following email address (psi@mci-group.com). Priority will also be given to questions submitted in advance.
PSI members will be asked to vote on a proposed merger between RSS and PSI from Friday 15th September. The voting will take place online with the results being announced at the extraordinary general meeting, Friday 28th October 2016.
More details, including the terms and answers to frequently asked questions are available at http://www.psiweb.org/rss. Please keep checking the website for updates.
This webinar will explore two different approaches to Correlates of Protection in vaccine development.
Our monthly webinar explores examples of innovative data visualisations relevant to our day to day work. Each month a new dataset is provided from a clinical trial or other relevant example, and participants are invited to submit a graphic that communicates interesting and relevant characteristics of the data.
The event will open with an overview on drug development in women’s health from a clinician perspective. This talk is followed by talks about statistical challenges when planning IVF studies and analysing the menstrual cycles.
This webinar will provide an overview of surrogacy for licensing and reimbursement. In turn, the need of extensions of the SPIRIT and CONSORT statement will be defined and outlined, with case studies to support.
Lea Vaas will present how replacement of concurrent control animals by Virtual Control Groups (VCGs) in systemic toxicity studies may help in contributing to the 3R's principle of animal experimentation: Reduce, Refine, Replace.
We will share a brief overview of what Mobilise D is and why it is an important step stone in the development of digital biomarkers, and how Mobilise D outputs can be relevant for you.
This networking event is aimed at statisticians that are new to the pharmaceutical industry who wish to meet colleagues from different companies and backgrounds.
This webinar will cover the history of cell/gene therapy, major regulatory advances, the role of quantitative scientists in drug development of these novel therapeutics, and discuss opportunities for innovation and product advancement.
This networking event is aimed at statisticians that are new to the pharmaceutical industry who wish to meet colleagues from different companies and backgrounds.
An introductory course giving an overview of the pharmaceutical industry and the drug development process as a whole, aimed at those with 1-3 years' experience. It comprises of six 2-day sessions covering a range of topics including Research and Development, Toxicology, Data Management and the Role of a CRO, Clinical Trials, Reimbursement, and Marketing.
This networking event is aimed at statisticians that are new to the pharmaceutical industry who wish to meet colleagues from different companies and backgrounds.
We have exciting new opportunities available for Study Statisticians, Support Statisticians and Exploratory Statisticians at various levels.